139 related articles for article (PubMed ID: 3053241)
1. T-cell depletion versus methotrexate as GvHD-prophylaxis in allogeneic bone marrow transplantation for leukaemia.
Wiesneth M; Hertenstein B; Bunjes D; Schmeiser T; Arnold R; Heimpel H; Heit W
Eur J Haematol; 1988 Sep; 41(3):243-9. PubMed ID: 3053241
[TBL] [Abstract][Full Text] [Related]
2. Relationship between graft-versus-host disease and graft-versus-leukaemia in partial T cell-depleted bone marrow transplantation.
van der Straaten HM; Fijnheer R; Dekker AW; Nieuwenhuis HK; Verdonck LF
Br J Haematol; 2001 Jul; 114(1):31-5. PubMed ID: 11472341
[TBL] [Abstract][Full Text] [Related]
3. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.
Hale G; Zhang MJ; Bunjes D; Prentice HG; Spence D; Horowitz MM; Barrett AJ; Waldmann H
Blood; 1998 Dec; 92(12):4581-90. PubMed ID: 9845524
[TBL] [Abstract][Full Text] [Related]
4. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow.
Filipovich AH; Vallera DA; Youle RJ; Haake R; Blazar BR; Arthur D; Neville DM; Ramsay NK; McGlave P; Kersey JH
Transplantation; 1987 Jul; 44(1):62-9. PubMed ID: 3299923
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
6. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial.
Wagner JE; Thompson JS; Carter SL; Kernan NA;
Lancet; 2005 Aug 27-Sep 2; 366(9487):733-41. PubMed ID: 16125590
[TBL] [Abstract][Full Text] [Related]
7. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
Aschan J; Ringdén O
Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
[TBL] [Abstract][Full Text] [Related]
9. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia.
Schots R; Van Riet I; Ben Othman T; Trullemans F; De Waele M; Van Camp B
Bone Marrow Transplant; 2001 Nov; 28(10):917-22. PubMed ID: 11753544
[TBL] [Abstract][Full Text] [Related]
10. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow.
Soiffer RJ; Murray C; Mauch P; Anderson KC; Freedman AS; Rabinowe SN; Takvorian T; Robertson MJ; Spector N; Gonin R
J Clin Oncol; 1992 Jul; 10(7):1191-200. PubMed ID: 1607923
[TBL] [Abstract][Full Text] [Related]
11. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
12. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
Hale G; Waldmann H
Bone Marrow Transplant; 1994 May; 13(5):597-611. PubMed ID: 8054913
[TBL] [Abstract][Full Text] [Related]
13. Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients.
Ringdén O; Pihlstedt P; Markling L; Aschan J; Båryd I; Ljungman P; Lönnqvist B; Tollemar J; Janossy G; Sundberg B
Bone Marrow Transplant; 1991 Mar; 7(3):221-6. PubMed ID: 2059758
[TBL] [Abstract][Full Text] [Related]
14. A prospective randomised trial of cyclosporin and methotrexate versus cyclosporin, methotrexate and prednisolone for prevention of graft-versus-host disease after HLA-identical sibling marrow transplantation for haematological malignancy.
Atkinson K; Biggs J; Concannon A; Dodds A; Young S; Wilson F; Ashby M; Downs K
Aust N Z J Med; 1991 Dec; 21(6):850-6. PubMed ID: 1818544
[TBL] [Abstract][Full Text] [Related]
15. Effective prevention of acute GVHD following allogeneic BMT with low leukaemic relapse using methotrexate and therapeutically monitored levels of cyclosporin A.
Hunter AE; Bessell EM; Russell NH
Bone Marrow Transplant; 1992 Nov; 10(5):431-4. PubMed ID: 1464005
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
[TBL] [Abstract][Full Text] [Related]
17. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse.
Naparstek E; Or R; Nagler A; Cividalli G; Engelhard D; Aker M; Gimon Z; Manny N; Sacks T; Tochner Z
Br J Haematol; 1995 Mar; 89(3):506-15. PubMed ID: 7734348
[TBL] [Abstract][Full Text] [Related]
18. T-cell depletion for bone marrow transplantation: effects on graft rejection, graft-versus-host disease, graft-versus-leukemia, and survival.
Champlin RE
Cancer Treat Res; 1990; 50():99-111. PubMed ID: 1976361
[TBL] [Abstract][Full Text] [Related]
19. Selective depletion of marrow-T cytotoxic lymphocytes (CD8) in the prevention of graft-versus-host disease after allogeneic bone-marrow transplantation.
Maraninchi D; Mawas C; Guyotat D; Reiffers J; Vernant JP; Gratecos N; Hirn J; Novakovitch G
Transpl Int; 1988 Jul; 1(2):91-4. PubMed ID: 3076387
[TBL] [Abstract][Full Text] [Related]
20. Results of four different protocols for prophylaxis against graft-versus-host disease.
Tollemar J; Ringdén O; Bäckman L; Janossy G; Lönnqvist B; Markling L; Philstedt P; Sundberg B
Transplant Proc; 1989 Feb; 21(1 Pt 3):3008-10. PubMed ID: 2650414
[No Abstract] [Full Text] [Related]
[Next] [New Search]
